Features

• Fast and simple to prepare, no diluting required
• It accelerates tissue regeneration thanks to its high concentration of growth factors that encourage cellular proliferation and migration
• High antifibrotic potential that encourages corneal transparency and protects against corneal scarring and leucomas
• Daily treatment with no need to store in the fridge as it can be used any time, anywhere

Indications

• Moderate to Severe Dry Eye
• Persistent Epithelial Defects
• Corrective Amyotrophia Surgery
• Burns, perforations, inflammation

Fibrine membrane
suturable autologous, strong, easy to handle and completely resorbable

Liquid plasma and Clot
enriched with Growth Factors

Eye drops
that maintain the growth factor supply after surgery

• Autologous
  Taken from the patient's blood, so there are no side effects.
• Optimum concentration of platelets
  An appropriate concentration of platelets that promote greater cellular proliferation.
• Patented activation
  Allows controlled release of growth factors.
• Leukocyte free formulation
  Endoret® does not contain leukocytes. Including leukocytes increases pain and inflammation and accelerates fibrin deterioration.

• No dilutions or preservatives
  Same pH and osmolarity as tears for greater regenerative potential and bio-safety.
• Reduces fibrosis
  Greater antifibrotic potential compared to SA.
• Reproducible
  Protocol is strictly defined and tested for the preparation process and clinical application.
• Versatile
  Different therapeutic formulations obtained in the same process help adapt the product to clinical needs.

• Stability guarantee
  Endoret eye drops® ( PRGF®) remain stable for 3 months when frozen and 72 hours at room temperature, maintaining biological and biosafety potential intact.
• Regulatory guarantees
  Endoret® ( PRGF®) has obtained the CE marking for use and sales in ophthalmology.
  
  The ENDORET® system meets all regulatory requirements as a closed technique, according to the standard from the Spanish Agency for Medicine and Healthcare Products dated 23rd May 2013, establishing the classification for non substitutive therapeutic use of autologous plasma and its parts, components or derivatives, as medicine for human use.

• Efficiency guarantees
  BTI has large-scale worldwide clinical support published in this field, upholding its effectiveness with more than 175 international scientific publications.
• Additional guarantees
  BTI certifies its customers' specific training to use this technology.
  
  BTI also guarantees traceability for its materials, and helps you provide your patients with all the necessary information.